In the anti-PD-1 Abs cohort, non-acral cutaneous type (HR, 0.33; 95% CI, 0.17–0.64; p = 0.0010) and median tumor thickness (HR, 0.36; 95% CI, 0.19–0.69; p = 0.0022) showed statistically significant differences in TTR (Table 1), while in the combined therapies cohort, there were no significant factors (p > 0.05, Supplementary Table S1). This evidence concerns the gene TTR and neoplasm.